[Immunovac-VP4 vaccine used in complex allergen-specific immunotherapy of patients with hay fever].
Assessment of clinical and immunological effects of use of bacterial therapeutic polycomponent vaccine Immunovac-VP4 for allergen-specific immunotherapy (ASIT) of hay fever. Five doses of Immunovac-VP4 vaccine consisted of antigens of opportunistic bacteria was used and administered by nasal-oral route. ASIT was performed with standard water-saline solution of allergens according to defined schedule. Sixty-nine patients with season rhinoconjunctivitis, asthma and their combinations were included in the study and divided to two groups. Skin scarification test was performed, total level of serum IgE, IgG4 and IgE to pollen allergens were measured by ELISA. Also, questionnaire was sent to patients yearly. Administration of bacterial therapeutic vaccine Immunovac-VP4 before start of ASIT resulted in marked clinical and immunological effect. In group of patients receiving combination therapy compared to control group, 8.5 times lower incidence of acute respiratory infections was registered. According to results of analysis of patients' questionnaires after 7 years, effectiveness of therapy was 90% that points to achievement of prolonged remission after completion of ASIT course. Utilization of natural ligands of Toll-like receptors is a perspective direction for development of new immunotherapeutic strategies for treatment of allergic diseases.